title: Everolimus in heart transplantation: does it finally have a home?
abstract: This editorial approves the use of everolimus to wean calcineurin inhibitors (by 7–11 weeks postoperative) as safe and effective with improved first-year renal function and reduced intimal thickness by intravascular ultrasound. See article by Andreassen et al on page 1828.
authors.forename: J A
authors.initials: JA
authors.lastname: Kobashigawa
authors.forename: A O
authors.initials: AO
authors.lastname: Zuckermann
mesh_terms: D065095:Calcineurin Inhibitors / Q000008:administration & dosage*; D000068338:Everolimus; D005260:Female; D016027:Heart Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
chemical_list: D065095:Calcineurin Inhibitors; D007166:Immunosuppressive Agents; D000068338:Everolimus; D020123:Sirolimus